Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting

European Journal of Pharmaceutical Sciences

Volumn 75, Issue , 2015, Pages 54-59

  Scheicher, B ^a   Schachner Nedherer, A L ^a   Zimmer, A ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antisense; CpG oligonucleotides; Protamine; siRNA

Indexed keywords

DNA BINDING PROTEIN; NANOPARTICLE; OLIGONUCLEOTIDE; PROTAMINE; SMALL INTERFERING RNA; IMMUNOLOGIC FACTOR;

DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG TARGETING; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ANIMAL; CHEMISTRY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; NANOPARTICLES; OLIGONUCLEOTIDES; PROTAMINES;

EID: 84929711904     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.04.009     Document Type: Review

References (63)

1. G. Almer, K.L. Summers, B. Scheicher, J. Kellner, I. Stelzer, G. Leitinger, A. Gries, R. Prassl, A. Zimmer, and H. Mangge Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions Int. J. Nanomed. 9 2014 4211 4222
2. G. Almer, K. Wernig, M. Saba-Lepek, S. Haj-Yahya, J. Rattenberger, J. Wagner, K. Gradauer, D. Frascione, G. Pabst, G. Leitinger, H. Mangge, A. Zimmer, and R. Prassl Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques Int. J. Nanomed. 6 2011 1279 1290
3. P.S. Apaolaza, D. Delgado, A.d. Pozo-Rodríguez, A.R. Gascón, and M.A. Solinís A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Int. J. Pharm. 465 2014 413 426
4. R. Balhorn The protamine family of sperm nuclear proteins Genome Biol. 8 2007 227
5. S. Bauer, C.J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. Wagner, and G.B. Lipford Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition Proc. Natl. Acad. Sci. U.S.A. 98 2001 9237 9242
6. W.M. Bertling, M. Gareis, V. Paspaleeva, A. Zimmer, J. Kreuter, E. Nurnberg, and P. Harrer Use of liposomes, viral capsids, and nanoparticles as DNA carriers Biotechnol. Appl. Biochem. 13 1991 390 405
7. F. Bianchi, R. Rousseaux-Prevost, C. Bailly, and J. Rousseaux Interaction of human P1 and P2 protamines with DNA Biochem. Biophys. Res. Commun. 201 1994 1197 1204
8. H. Braun, K. Boller, J. Lower, W.M. Bertling, and A. Zimmer Oligonucleotide and plasmid DNA packaging into polyoma VP1 virus-like particles expressed in Escherichia coli Biotechnol. Appl. Biochem. 29 Pt 1 1999 31 43
9. C.-H. Chang, B. Paul, V. Remcho, S. Atre, and J. Hutchison Synthesis and post-processing of nanomaterials using microreaction technology J. Nanopart. Res. 10 2008 965 980
10. Y. Chen, S.R. Bathula, Q. Yang, and L. Huang Targeted nanoparticles deliver siRNA to melanoma J. Invest. Dermatol. 130 2010 2790 2798
11. S. Chono, S.D. Li, C.C. Conwell, and L. Huang An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor J. Controlled Release: Official J. Controlled Release Soc. 131 2008 64 69
12. R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann, and C.V. Harding CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity J. Exp. Med. 186 1997 1623 1631
13. D. Delgado, A. del Pozo-Rodriguez, M.A. Solinis, M. Aviles-Triqueros, B.H. Weber, E. Fernandez, and A.R. Gascon Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis Hum. Gene Ther. 23 2012 345 355
14. N. Dias, and C.A. Stein Antisense oligonucleotides: basic concepts and mechanisms Mol. Cancer Ther. 1 2002 347 355
15. N. Dinauer, D. Lochmann, I. Demirhan, A. Bouazzaoui, A. Zimmer, A. Chandra, J. Kreuter, and H. von Briesen Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation J. Controlled Release: Official J. Controlled Release Soc. 96 2004 497 507
16. DPMAregister, 1999. Available from: < https://register.dpma.de/DPMAregister/marke/register/399178813/DE > (Accessed 01.12.15).
17. M. Dul, K.J. Paluch, H. Kelly, A.M. Healy, A. Sasse, and L. Tajber Self-assembled carrageenan/protamine polyelectrolyte nanoplexes - investigation of critical parameters governing their formation and characteristics Carbohydr. Polym. 123 2015 339 349
18. A. Eitzlmayr, C. Petschacher, S. Radl, D. Suzzi, A. Zimmer, and J.G. Khinast Modeling and simulation of polyacrylic acid/protamine nanoparticle precipitation Soft Matter 7 2011 9484 9497
19. H. Faneca, S. Simões, and M.C. Pedroso de Lima Association of albumin or protamine to lipoplexes: enhancement of transfection and resistance to serum J. Gene Med. 6 2004 681 692
20. D. Fischer, T. Bieber, S. Brüsselbach, H.-P. Elsässer, and T. Kissel Cationized human serum albumin as a non-viral vector system for gene delivery? characterization of complex formation with plasmid DNA and transfection efficiency Int. J. Pharm. 225 2001 97 111
21. X. Gao, and L. Huang Potentiation of cationic liposome-mediated gene delivery by polycations† Biochemistry 35 1996 1027 1036
22. G. Hartmann, J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells Eur. J. Immunol. 33 2003 1633 1641
23. H. He, J. Ye, E. Liu, Q. Liang, Q. Liu, and V.C. Yang Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide J. Controlled Release: Official J. Controlled Release Soc. 193C 2014 63 73
24. L.H. Hung, and A.P. Lee Microfluidic devices for the synthesis of nanoparticles and biomaterials J. Med. Biol. Eng. 27 2007 1 6
25. M. Junghans, J. Kreuter, and A. Zimmer Antisense delivery using protamine-oligonucleotide particles Nucleic Acids Res. 28 2000 E45
26. Junghans, M., Kreuter, J., Zimmer, A., 2000. Synthetic nucleic acid particle. WO2000036131 A1.
27. M. Junghans, J. Kreuter, and A. Zimmer Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles Biochim. Biophys. Acta 1544 2001 177 188
28. M. Junghans, S.M. Loitsch, S.C.J. Steiniger, J. Kreuter, and A. Zimmer Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides Eur. J. Pharm. Biopharm. 60 2005 287 294
29. M. Kerkmann, D. Lochmann, J. Weyermann, A. Marschner, H. Poeck, M. Wagner, J. Battiany, A. Zimmer, S. Endres, and G. Hartmann Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles Oligonucleotides 16 2006 313 322
30. I. Kratzer, K. Wernig, U. Panzenboeck, E. Bernhart, H. Reicher, R. Wronski, M. Windisch, A. Hammer, E. Malle, A. Zimmer, and W. Sattler Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier J. Control. Release 117 2007 301 311
31. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 2002 317 325
32. A.M. Krieg, A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
33. M. Lemaitre, B. Bayard, and B. Lebleu Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site Proc. Natl. Acad. Sci. U.S.A. 84 1987 648 652
34. A.A. Levin A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides Biochim. Biophys. Acta (BBA) - Gene Struct. Expression 1489 1999 69 84
35. S. Li, M.A. Rizzo, S. Bhattacharya, and L. Huang Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery Gene Ther. 5 1998 930 937
36. M. Lindgren, M. Hallbrink, A. Prochiantz, and U. Langel Cell-penetrating peptides Trends Pharmacol. Sci. 21 2000 99 103
37. D. Lochmann, V. Vogel, J. Weyermann, N. Dinauer, H. von Briesen, J. Kreuter, D. Schubert, and A. Zimmer Physicochemical characterization of protamine-phosphorothioate nanoparticles J. Microencapsul. 21 2004 625 641
38. D. Lochmann, J. Weyermann, C. Georgens, R. Prassl, and A. Zimmer Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization Eur. J. Pharm. Biopharm. 59 2005 419 429
39. H. Mangge, G. Almer, I. Stelzer, E. Reininghaus, and R. Prassl Laboratory medicine for molecular imaging of atherosclerosis Clin. Chim. Acta; Int. J. Clin. Chem. 437 2014 19 24
40. J.M. Martinez Gomez, S. Fischer, N. Csaba, T.M. Kundig, H.P. Merkle, B. Gander, and P. Johansen A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles Pharm. Res. 24 2007 1927 1935
41. G. Mayer, V. Vogel, J. Weyermann, D. Lochmann, J.A. van den Broek, C. Tziatzios, W. Haase, D. Wouters, U.S. Schubert, A. Zimmer, J. Kreuter, and D. Schubert Oligonucleotide-protamine-albumin nanoparticles: protamine sulfate causes drastic size reduction J. Control. Release 106 2005 181 187
42. F. Miescher Das Protamin, eine neue organische Base aus den Samenfäden des Rheinlachses Ber. Dtsch. Chem. Ges. 7 1874 376 379
43. D.J. Mitchell, D.T. Kim, L. Steinman, C.G. Fathman, and J.B. Rothbard Polyarginine enters cells more efficiently than other polycationic homopolymers J. Pept. Res.: Official J. Am. Pept. Soc. 56 2000 318 325
44. A. Ortner, K. Wernig, R. Kaisler, M. Edetsberger, F. Hajos, G. Kohler, W. Mosgoeller, and A. Zimmer VPAC receptor mediated tumor cell targeting by protamine based nanoparticles J. Drug Target. 18 2010 457 467
45. D.R. Owens Insulin preparations with prolonged effect Diabetes Technol. Ther. 13 Suppl 1 2011 S5 14
46. I. Pali-Scholl, H. Szollosi, P. Starkl, B. Scheicher, C. Stremnitzer, A. Hofmeister, F. Roth-Walter, A. Lukschal, S.C. Diesner, A. Zimmer, and E. Jensen-Jarolim Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice Eur. J. Pharm. Biopharm. 85 2013 656 664
47. C. Petschacher, A. Eitzlmayr, M. Besenhard, J. Wagner, J. Barthelmes, A. Bernkop-Schnurch, J.G. Khinast, and A. Zimmer Thinking continuously: a microreactor for the production and scale-up of biodegradable, self-assembled nanoparticles Polym. Chem. 4 2013 2342 2352
48. E. Raukas, and R.H. Mikelsaar Are there molecules of nucleoprotamine? BioEssays: News Rev. Mol. Cell. Dev. Biol. 21 1999 440 448
49. D. Reischl, and A. Zimmer Drug delivery of siRNA therapeutics: potentials and limits of nanosystems Nanomed. Nanotechnol. Biol. Med. 5 2009 8 20
50. V.Z. Rocha, and P. Libby Obesity, inflammation, and atherosclerosis Nat. Rev. Cardiol. 6 2009 399 409
51. S. Simoes, V. Slepushkin, P. Pires, R. Gaspar, M.C. Pedroso de Lima, and N. Duzgunes Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum Biochim. Biophys. Acta 1463 2000 459 469
52. F.L. Sorgi, S. Bhattacharya, and L. Huang Protamine sulfate enhances lipid-mediated gene transfer Gene Ther. 4 1997 961 968
53. K.M. Stewart, K.L. Horton, and S.O. Kelley Cell-penetrating peptides as delivery vehicles for biology and medicine Org. Biomol. Chem. 6 2008 2242 2255
54. A. Umerska, K.J. Paluch, M.-J.S. Martinez, O.I. Corrigan, C. Medina, and L. Tajber Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers J. Biomed. Nanotechnol. 10 2014 3658 3673
55. V. Vogel, D. Lochmann, J. Weyermann, G. Mayer, C. Tziatzios, J.A. van den Broek, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, A. Zimmer, and D. Schubert Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular' distribution J. Control. Release 103 2005 99 111
56. Y. Wang, Z. Xu, S. Guo, L. Zhang, A. Sharma, G.P. Robertson, and L. Huang Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis Mol. Ther. 21 2013 1919 1929
57. H. Wartlick, B. Spankuch-Schmitt, K. Strebhardt, J. Kreuter, and K. Langer Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles J. Controlled Release: Official J. Controlled Release Soc. 96 2004 483 495
58. K. Wernig, M. Griesbacher, F. Andreae, F. Hajos, J. Wagner, W. Mosgoeller, and A. Zimmer Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles J. Control. Release 130 2008 192 198
59. J. Weyermann, D. Lochmann, C. Georgens, and A. Zimmer Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect Eur. J. Pharm. Biopharm. 59 2005 431 438
60. J. Weyermann, D. Lochmann, and A. Zimmer Comparison of antisense oligonucleotide drug delivery systems J. Control. Release 100 2004 411 423
61. H. Xia, X. Gao, G. Gu, Z. Liu, N. Zeng, Q. Hu, Q. Song, L. Yao, Z. Pang, X. Jiang, J. Chen, and H. Chen Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration Biomaterials 32 2011 9888 9898
62. Z. Xu, Y. Wang, L. Zhang, and L. Huang Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment ACS Nano 8 2014 3636 3645
63. A. Zimmer, S. Atmaca-Abdel Aziz, M. Gilbert, D. Werner, and C.R. Noe Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides Eur. J. Pharm. Biopharm. 47 1999 175 178